×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Kidney

Jason M. Broderick
Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma. 
Angelica Welch
There are 16 known genes that cause kidney cancer and at least 13 different types of inherited kidney cancer, emphasizing the need to understand genetic differences between these disease.
Brielle Urciuoli
James Brugarolas, M.D., Ph.D., discusses the importance of spotting the difference between a metastatic kidney cancer lesion and a separate lung cancer. The difference can save patients' lives.
Angelica Welch
David McDermott, M.D. discusses new advances made to treat kidney cancer. 
Silas Inman
An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open. 
A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.
Lauren M. Green
A recent study found that patients with metastatic renal cell carcinoma may see extended response even after stopping immunotherapy treatment.
Lisa Miller
Patients with metastatic kidney cancer may see a decreased efficacy of their immunotherapy regimen if they recently took antibiotics.
Danielle Bucco
Sutent treatment breaks seem to have no effect on clinical efficacy for patients with renal cell carcinoma.
Angelica Welch
CURE spoke with Neeraj Agarwal, M.D., about the underreporting and underemphasizing of toxicities with PD-1 inhibitors in renal cell carcinoma.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable